Hepion (HEPA) falls 0.63% on Moderate Volume September 16

Equities Staff  |

Today, Hepion Pharmaceuticals Inc Inc’s (NASDAQ: HEPA) stock fell $0.01, accounting for a 0.63% decrease. Hepion opened at $1.57 before trading between $1.59 and $1.54 throughout Thursday’s session. The activity saw Hepion’s market cap fall to $120,435,887 on 719,877 shares -below their 30-day average of 2,207,933.

About Hepion Pharmaceuticals Inc

The Company's lead drug candidate, CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes. CRV431 is currently in clinical-phase development for the treatment of NASH, with the potential to play an important role in the overall treatment of liver disease - from triggering events through to end-stage disease. CRV431 has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH; and has demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms, in preclinical studies. Hepion has created a proprietary AI platform, called AI-POWR™, which stands for Artificial Intelligence - Precision Medicine; Omics (including genomics, proteomics, metabolomics, transcriptomics, and lipidomics); World database access; and Response and clinical outcomes. Hepion intends to use AI-POWR™ to help identify which NASH patients will best respond to CRV431, potentially shortening development timelines and increasing the delta between placebo and treatment groups. In addition to using AI-POWR™ to drive its ongoing Phase 2a NASH program, Hepion will use the platform to identify additional potential indications for CRV431 to expand the company's footprint in the cyclophilin inhibition therapeutic space.

Visit Hepion Pharmaceuticals Inc's profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Hepion Pharmaceuticals Inc and to follow the company's latest updates, you can visit the company's profile page here: Hepion Pharmaceuticals Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

McDonald's To Offer New Plant-Based Burger in US Restaurants by Beyond Meat
Walgreens Investing Additional $5.2 Billion in Primary Care Provider VillageMD
JPMorgan Misses on Third Quarter Revenue, Beats Earnings Estimates With One-Time Items
BlackRock Beats Q3 Profit Estimates, But Asset Growth Flattens
Emerson Electric To Merge Industrial Software Businesses With Aspen Technology
Facebook Willing To Accept More Oversight and Regulation
Amazon Offering Greater Flexibility for Employees To Work Remotely
California To Ban Sales of Gasoline-Powered Lawn Equipment



Market Movers

Sponsored Financial Content